We are currently able to prescribe Wegovy to patients that meet the NICE criteria:

BMI ≥35  and at least one weight related co-morbidity (e.g. non-diabetic hyperglycaemia, type 2 diabetes, hypertension, sleep apnoea, fatty liver etc)

However, due to limited capacity, we are prioritising patients with highest clinical need (such as needing to lose weight for cancer treatment or transplant surgery for example) and so patients with a low priority will not be accepted if weight loss injections are the only reason they are being referred.

Please consider prescribing medications such as tirzepatide (Mounjaro) for patients who have uncontrolled type 2 diabetes and who would benefit from weight loss.

From June 23rd 2025, Tirzepatide will be available in primary for the indication of weight loss (as per the NICE funding variation) for the following patients:

BMI ≥ 40 kg/m²

AND

4 0r more qualifying conditions, from type 2 diabetes, cardiovascular disease (IHD, stroke, heart failure, peripheral vascular disease), hypertension, dyslipidaemia, Obstructive sleep apnoea (confirmed via sleep studies and treatment with CPAP indicated).

If patients would consider taking part in research trials of new weight loss drugs, they can register their interest by contacting Getinvolved@SomersetFT.nhs.uk

Update on Weight loss medications and advice when stopping